Current Market Access to Atopic Dermatitis Medications

The FDA in February accepted a New Drug Application under priority review for Incyte Corp.’s ruxolitinib cream for the treatment of atopic dermatitis. Meanwhile, there are currently more than 10 agents in Phase III trials for this indication. Among the medications that are on the market, Sanofi and Regeneron’s Dupixent (dupilumab) and Pfizer Inc.’s Eucrisa (crisaborole) are competing for preferred status after topical corticosteroids, topical calcineurin inhibitors and phototherapy. Most medications are covered under the pharmacy benefit, with the exception of Dupixent. More than half of payer pharmacy benefit formularies do not require step therapy or prior authorization for atopic dermatitis medications.

NOTE: Under the pharmacy benefit, the total covered lives under commercial, health exchange, Medicare and Medicaid formularies are 170.0 million, 11.7 million, 47.8 million and 69.8 million, respectively. Under the medical benefit, the total covered lives under commercial, health exchange, Medicare and Medicaid formularies are 168.4 million, 11.7 million, 49.5 million and 69.8 million, respectively.

SOURCE: Managed Markets Insight & Technology, LLC database as of May 2021.

Jinghong Chen

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

businessmen-pointing-at-a-cellphone
January 19

Industry Will Continue to See 340B, Patient-Paid Prescription Impact as IRA Looms

Read More
a-doctor-giving-injection
January 19

FDA Approves Gilead’s First-in-Class HIV Drug Sunlenca

Read More
two-business-people-typing-on-a-tablet
January 19

New Organization Will Focus on Medical Benefit Drugs

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today